(Q37767367)

22 August 2017

1 reference

title

Targeted treatment and new agents in follicular lymphoma (English)

1 reference

22 August 2017

Bruce D Cheson

1 reference

22 August 2017

publication date

24 June 2010

1 reference

International Journal of Hematology

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

5-11

1 reference

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0608-7

Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are functionally active in an ex vivo flow model of thrombosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0608-7

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

12 December 2020

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics

1 reference

12 December 2020

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

1 reference

12 December 2020

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

1 reference

12 December 2020

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

1 reference

12 December 2020

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

1 reference

12 December 2020

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma

1 reference

12 December 2020

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases

1 reference

12 December 2020

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

1 reference

12 December 2020

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

1 reference

12 December 2020

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

1 reference

12 December 2020

New treatment options have changed the survival of patients with follicular lymphoma

1 reference

12 December 2020

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

1 reference

12 December 2020

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

12 December 2020

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

12 December 2020

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

1 reference

12 December 2020

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

1 reference

12 December 2020

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

1 reference

12 December 2020

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

1 reference

12 December 2020

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

12 December 2020

Lenalidomide for the treatment of B-cell malignancies

1 reference

12 December 2020

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

12 December 2020

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

1 reference

12 December 2020

10.1007/S12185-010-0608-7

Identifiers

DOI

1 reference

22 August 2017

1 reference